方文峰
专长
一、基本情况
专科门诊时间：越秀院区周一下午、周四上午，黄埔院区周二上午、周三下午
二、教育及工作经历
教育经历
2006.09-2011．06 武汉大学 肿瘤学 博士
2007.10-2009.10 美国伊利诺伊大学芝加哥分校 肿瘤学 联合培养博士
2002.09-2005.06 武汉大学 生命科学 第二学士学位
2001.09-2006.07 武汉大学 临床医学 本科
工作经历
2023.01- 至今 中山大学肿瘤防治中心 内科 教授
2020.12 - 至今 中山大学肿瘤防治中心 内科 主任医师
2016.01-2020.12 中山大学肿瘤防治中心 内科 副主任医师
2014.01-2015.12 中山大学肿瘤防治中心 内科 主治医师
2013.05-2013.09 美国加州大学洛杉矶分校进修学习；
2012.09-2013.12 中山大学肿瘤防治中心 内科 专科医师
2011.08-2012.08 中山大学肿瘤防治中心 内科 住院医师
三、学术兼职
中国医药教育协会创新药临床与转化研究专业委员会主任委员
中国抗癌协会非小细胞肺癌专业委员会常委
CSCO非小细胞肺癌专业委员会委员
CSCO鼻咽癌专业委员会委员
中国初级卫生保健基金会少见罕见突变肿瘤专业委员会主任委员
中国人体健康科技促进会细胞免疫治疗专业委员会副主任委员
广东省抗癌协会鼻咽癌专业青年委员会副主任委员
广东省医学会精准医学与分子诊断专业委员会副主任委员
广东省胸部疾病学会遗传学专委会副主任委员
广东市抗癌协会分子靶向治疗专业委员会副主任委员
广东省抗癌协会化疗专业青年委员会常委
广东省胸部疾病协会免疫治疗专业委员会常委
广东省临床医学会精准医疗专业委员会委员
广东省转化医学学会肿瘤学分会委员
四、主持科研项目
1. 2025年，省科技重大专项“创新生物药”，多肽蛋白及抗体药物长效化关键技术研究（课题负责人）
2. 2023年，国家自然科学基金，面上项目，EGFR通过CCL2和CD47介导肿瘤相关巨噬细胞调控在EGFR突变肺癌免疫“冷肿瘤”形成中的作用及机制研究；2024.01-2027.12，（主持）
3. 2021年，国家高层次人才青年项目，2021.12-2024.11，（主持）
4. 2021年，国家自然科学基金，面上项目，EGFR对PCSK9及MHC-I/II类分子调控在EGFR突变肺癌免疫治疗耐药中的作用及克服耐药新策略研究，2022.01-2025.12, (主持)
5. 2019年，国家自然科学基金，面上项目，EBV 潜伏膜蛋白 LMP1介导 MHC-I/II抑制和 PD-L1 上调在鼻咽癌免疫逃逸中的作用及联合免疫治疗策略探索，2020.01-2021.12, (主持)
6. 2018年，重大新药创制国家科技基金，重大专项，新型靶向抗肿瘤1类新药 ACC006 临床研究 (子课题)，2018.01-2020.12 (主持)
7. 2018年，中山大学肿瘤防治中心308项目，安罗替尼联合吉非替尼对比安慰剂联合吉非替尼一线治疗ⅢB-Ⅳ期EGFR基因突变型非小细胞肺癌患者的多中心、随机、双盲、平行对照III期临床研究，2018.01-2028.12 (主持)
8. 2017年，国家自然科学基金，面上项目，EGFR对MHC-I/II分子和PD-L1的调控在肺癌免疫逃逸中的作用及免疫治疗策略研究，2018.01-2021.12 (主持)
9. 2016年，CSCO—恒瑞肿瘤研究基金，阿帕替尼的免疫增强效应与抗PD-1抗体 （SHR1210）联合治疗NSCLC的临床探索性研究 , 2017.01-2019.12 (主持)
10. 2015年，广东省科技计划项目，鼻咽癌抗PD-1免疫治疗疗效预测标志物研究， 2016.01-2018.12 (主持)
11. 2015年，广东省特支计划“百千万工程青年拔尖人才” (主持)
12. 2015年，CSCO—恒瑞肿瘤研究基金，新生血管周细胞表达 PD-L1 介导的肿瘤免疫逃逸及阿帕替尼对 NSCLC 免疫增强作用的研究，2016.06-2019.05 (主持)
13. 2015年，国家自然科学基金，面上项目，鼻咽癌PD-L1广泛表达的分子机制及逃逸作用研究，2016.01-2019.12， (主持)
14. 2015年，广州市科技计划（珠江科技新星项目）， EBV 感染驱动鼻咽癌 PD-L1表达的分子机制及免疫逃逸作用研究，2016.05-2019.04 (主持)
15. 2015年，CSCO—默克雪兰诺肿瘤研究基金，EGFR介导的PD-L1调控及西妥昔单抗对鼻咽癌的免疫增强作用研究，2016.01-2018.12 (主持)
16. 2014年，中山大学青年教师培育项目，AXL激酶激活在肺癌EGFR-TKIs 非经典型获得性耐药中的作用及其机制研究，2014.06- 2017.06 (主持)
17. 2014年，中山大学肿瘤防治中心“临床医学科学家”项目，PD-L1介导的鼻咽癌免疫逃逸机制研究，2015.01- 2019.12 (主持)
18. 2013年，中山大学肿瘤防治中心优秀人才培育项目，鼻咽癌免疫逃逸机制研究，2014.01-2018.12 (主持)
19. 2012年，国家自然科学基金，青年项目，SBP1 对SOD1/2 的调节及其在结直肠癌细胞耐受活性氧应激中的作用，2013.01-2015.12 (主持)
20. 2012年，教育部博士点青年教师培育项目，SBP1在结直肠癌细胞耐受活性氧应激中的作用，2013.01-2015.12 (主持)
五、代表性论著
1. Wenfeng Fang（方文峰）#, Lin Wu , Xiangjiao Meng , Yu Yao , Wei Zuo , Wenxiu Yao , Yanyan Xie , Yu Zhang , Jiuwei Cui , Yongchang Zhang , Xingya Li , Wu Zhuang , Jian Fang , Qiming Wang , Wei Jiang , Kai Li , Yuju Bai , Yongzhong Luo , Fang Ma , Yan Yu , Wei Zheng , Zhentian Liu , Bin Yang , Rui Ma , Yong Fang , Runxiang Yang , Liyan Jiang , Jie Hu , Jiacheng Yang , Yina Diao , Xiaoping Jin , Junyou Ge , Yunpeng Yang , Li Zhang*. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Oct 19
2. Wenfeng Fang（方文峰）#, Yuanyuan Zhao#, Yongzhong Luo#, Runxiang Yang#, Yan Huang#, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibing Song, Xiaobo Du, Yulan Sun, Wei Li, Fei Xu, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Junguo Lu, Jifeng Feng, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, Weineng Feng, Wen Li, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Zhang*. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer with EGFR Variant. JAMA. 2024 May 31;332(7):561–570.
3. Wenfeng Fang#(方文峰) , Xingya Li , Qiming Wang , Xiangjiao Meng , Wei Zheng, Longhua Sun , Wenxiu Yao , Wu Zhuang , Yun Fan , Minglei Zhuo ， Yongzhong Luo , Zhiye Zhang , Xia Song , Runxiang Yang , Jiacheng Yang , Xiaoping Jin , Yina Diao , Junyou Ge , Li Zhang *. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. Bmj-british Medical Journal. 2025 Jun 5;389:e085680.
4. Shen Zhao#,Ying Cheng,Qiming Wang,Xingya Li,Jun Liao,Jordi Rodon,XiangjiaoMeng,Yongzhong Luo, Zhendong Chen, Wei Wang,Tienan Yi,Yongsheng Li,Yongmei Yin , Huiting Xu, Guohua Yu, Yanjun Mi, Yun Fan, Zev A Wainberg,Xiang Wang, Cuiyun Su, Qitao Yu,Shuzhen Lai, Longhua Sun, Wu Zhuang,Xian Wang,Jiacheng Yang,Yaling Li,Junyou Ge,Jin Li,Li Zhang*,Wenfeng Fang(方文峰)*. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med. 2025 Jun;31(6):1976-1986.
5. Shaodong Hong, Qiming Wang, Ying Cheng, Yongzhong Luo, Xiujuan Qu, Haibo Zhu, Zhenyu Ding, Xingya Li, Lin Wu, Yan Wang, Sheng Hu, Enwen Wang, Anwen Liu, Yuping Sun, Yun Fan, Feng Ye, Kaihua Lu, Jian Fang, Yuping Shen, Xiaoping Jin, Junyou Ge, Li Zhang *，Wenfeng Fang(方文峰)*. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025 Nov;31(11):3654-3661.
6. Yunpeng Yang#, Jianji Pan , Hui Wang , Yuanyuan Zhao , Shenhong Qu , Nianyong Chen , Xiaozhong Chen , Yan Sun , Xiaohui He , Chaosu Hu , Lizhu Lin , Qitao Yu , Siyang Wang , Guihua Wang , Feng Lei , Jiyu Wen , Kunyu Yang , Zhixiong Lin , Ye Guo , Shaoqing Chen , Xiaoming Huang, Yanjie Wu, Liang Liang , Chenqi Chen , Fan Bai , Xiaopeng Ma , Yun Zhang , Shiangjiin Leaw , Li Zhang *, Wenfeng Fang（方文峰）*. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061-1072.e4.
7. Shaodong Hong#, Yaxiong Zhang#, Gengsheng Yu#, Peijian Peng#, Jiewen Peng#, Jun Jia, Xuan Wu, Yan Huang#, Yunpeng Yang, Qing Lin, Xuping Xi, Mingjun Xu, Dongping Chen, Xiaojun Lu, Rensheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao, Wenfeng Fang（方文峰）*, Li Zhang*. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or METastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology. 2021 Aug; JCO2100396.
8. Yunpeng Yang#, Song Qu#, Jingao Li#, Chaosu Hu#, Mingjun Xu#, Weidong Li#, Ting Zhou#, Liangfang Shen, Hui Wu, Jinyi Lang, Guangyuan Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Feng Lei, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiaojing Zhang, Jianjun Zou, Wenfeng Fang（方文峰）*, Li Zhang*. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or METastatic nasopharyngeal carcinoma: a multicenter, randomized, double-blind, phase 3 trial. Lancet Oncology. 2021 Aug; 22(8): 1162-1174.
9. Wenfeng Fang（方文峰） #, Yunpeng Yang#, Yuxiang Ma#, Shaodong Hong#, Lizhu Lin#, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang*. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncology. 2018 Oct;19(10):1338-1350.
10. Hua-Qiang Zhou#, Ya-Xiong Zhang#, Gang Chen#, Qi-Tao Yu#, Hua Zhang#, Guo-Wu Wu, Di Wu, Ying-Cheng Lin, Jun-Fei Zhu, Jian-Hua Chen, Xiao-Hua Hu, Bin Lan, Ze-Qiang Zhou, Hai-Feng Lin, Zi-Bing Wang, Xiao-Lin Lei, Suo-Ming Pan, Li-Ming Chen, Jian Zhang, Tian-Dong Kong, Ji-Cheng Yao, Xin Zheng, Feng Li, Li Zhang*, Wen-Feng Fang（方文峰）*. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated,EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial. Signal Transduct Target Ther. 2024 Aug 13;9:215.
11. Yan Huang #, Yunpeng Yang#, Yuanyuan Zhao#, Hongyun Zhao#, Ningning Zhou #, Yaxiong Zhang#, Likun Chen Ting Zhou , Gang Chen , Ting Wu, Lu Lu , Shilin Xue, Xiaoyan Kang , Li Zhang* , Wenfeng Fang（方文峰）* . QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal Transduct Target Ther. 2024;9(1):23.
12. Yaxiong Zhang # , Yan Huang # , Yunpeng Yang # , Yuanyuan Zhao # , Ting Zhou # , Gang Chen , Shen Zhao , Huaqiang Zhou , Yuxiang Ma , Shaodong Hong , Hongyun Zhao , Li Zhang *, Wenfeng Fang（方文峰） *. Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial. Signal Transduct Target Ther. 2024;9(1):255.
13. Yunpeng Yang#, Jie Min #, Nong Yang#, Qitao Yu#, Ying Cheng#, Yanqiu Zhao , Manxiang Li , Hong Chen , Shou'an Ren , Jianying Zhou, Wu Zhuang , Xintian Qin , Lejie Cao , Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu , Li Zhang* , Wenfeng Fang（方文峰）*. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct Target Ther. 2023;8(1):301.
14. Yaxiong Zhang#, Yan Huang#, Yunpeng Yang#, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Likun Chen, Ting Zhou, Gang Chen, Shen Zhao, Huaqiang Zhou, Hui Li, Xiaoyan Kang, Li Zhang* ,Wenfeng Fang(方文峰)* .Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study. J Hematol Oncol. 2025 Jul 26;18(1):75.
15. Wenfeng Fang（方文峰）#, Haoxuan Jin#, Huaqiang Zhou#, Shaodong Hong#, Yuxiang Ma, Yaxiong Zhang, Xiaofan Su, Longyun Chen, Yunpeng Yang, Shengqiang Xu, Yuwei Liao, Yuming He, Hongyun Zhao, Yan Huang, Zhibo Gao* and Li Zhang*. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non- small cell lung cancer. Molecular Cancer, 2021 Feb; 20 (1):37.
16. Yaxiong Zhang#, Lianpeng Chang#, Yunpeng Yang#, Wenfeng Fang（方文峰）#, Yanfang Guan#, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang, Xin Wang, Zhesheng Wen, Junye Wang, Hong Yang, Xuefeng Xia, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Zhonghan Zhang, Jianhua Zhan, Yan Huang, Hongyun Zhao, Ningning Zhou, Xin Yi and Li Zhang*. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular Cancer, 2019 Jan; 18(1):7.
17. Li-Yang Hu#, Wei-Tao Zhuang #, Mao-Jian Chen, Jun Liao , Dong-Fang Wu , Ya-Xiong Zhang , Lan-Lan Pang, Yi-Hua Huang, Tian-Qin Mao, Meng-Juan Yang , Pei-Jian Peng , Jin-Xia Liang , Liang Chen , Lin-Juan Zeng , Li Zhang , Wen-Feng Fang（方文峰） *. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47. Journal of Thoracic Oncology. 2024 Aug;19(8):1186-1200.
18. Wenfeng Fang（方文峰）#, Yihua Huang#, Jiadi Gan, Qiufan Zheng, Li Zhang*. Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy. Journal of Thoracic Oncology; 2020 Mar; 15(3): E36-E37.
19. Wenfeng Fang（方文峰）#, Yihua Huang#, Jiadi Gan, Bishan He, Li Zhang*. Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia. Journal of Thoracic Oncology; 2020 Mar; 15(3): E34-E35.
20. Huaqiang Zhou #, Jiayi Shen , Jiaqing Liu, Wenfeng Fang（方文峰） *, Li Zhang *. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC. Journal of Thoracic Oncology. 2020 Aug;15(8):e133-e136.
21. Yihua Huang#, Jiadi Gan#, Kunbin Guo, Yangyang Deng, Wenfeng Fang（方文峰）*. Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and TraMETinib Combination Therapy. Journal of Thoracic Oncology; 2019 Oct; 14(10): E236-E237.
22. Lan-Lan Pang#; Wei-Tao Zhuang#; Zi-Hong Chen#，Jun Liao ; Meng-Di Li ; Li Zhang*;Wen-Feng Fang（方文峰）*; Ya-Xiong Zhang*.Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.JNatl Compr Canc Netw.2025 Mar 13;23(4):e247092
23. Shen Zhao # , Wu Zhuang # , Baohui Han # , Zhengbo Song #, Wei Guo # , Feng Luo # , Lin Wu , Yi Hu , Huijuan Wang , Xiaorong Dong , Da Jiang , Mingxia Wang , Liyun Miao , Qian Wang , Junping Zhang , Zhenming Fu , Yihua Huang , Chunwei Xu , Longyu Hu , Lei Li , Rong Hu , Yang Yang , Mengke Li , Xiugao Yang , Li Zhang , Yan Huang , Wenfeng Fang（方文峰）*. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat Commun. 2023 Jun 12;14(1):3468.
24. Zihong Chen#, Gang Chen , Yuxiang Ma , Hongyun Zhao , Jianhua Zhan, Yan Huang , Yunpeng Yang , Yuanyuan Zhao , Shaodong Hong , Ting Zhou, Wenfeng Fang（方文峰）* , Li Zhang , Yaxiong Zhang. Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors. MedComm (2020). 2025 Jul 9;6(7):e70272.
25. Yihua Huang #, Yuanyuan Zhao #, Yan Huang #, Yunpeng Yang #, Yaxiong Zhang #, Shaodong Hong , Hongyun Zhao , Shen Zhao , Ting Zhou , Gang Chen , Huaqiang Zhou , Yuxiang Ma , Ningning Zhou , Li Zhang , Wenfeng Fang（方文峰）* .Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer. MedComm. 2024 Apr 29;5(5):e536.
26. Yunpeng Yang#, Ting Zhou#, Xiaozhong Chen#, Jingao Li#, Jianji Pan#, Xiaohui He, Lizhu Lin, Ying-rui Shi, Weineng Feng, Jianping Xiong, Kunyu Yang, Qitao Yu, Qunling Zhang, Desheng Hu, Yan Sun, Guangyuan Hu, Ping Li, Liangfang Shen, Qin Lin, Ben Zhang, Xiao Qu, Jianjun Zou, Li Zhang, Wenfeng Fang (方文峰)*, Yuanyuan Zhao*. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or METastatic Nasopharyngeal Carcinoma (CAPTAIN study). Journal for ImmunoTherapy of Cancer; 2021; 9(12): e003790.
27. Yuxiang Ma#, Xi Chen#, Ao Wang#, Hongyun Zhao#, Qingguang Lin, Hua Bao, Yang Zhang, Shaodong Hong, Wanxiangfu Tang, Yan Huang, Yunpeng Yang, Xue Wu, Yang Shao, Wenfeng Fang（方文峰）*, Li Zhang*. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. Journal for ImmunoTherapy of Cancer; 2021; 9(3): e002014.
28. Yuanyuan Zhao# , Gang Chen , Jianhua Chen , Li Zhuang , Yingying Du , Qitao Yu , Wu Zhuang , Yanqiu Zhao , Ming Zhou , Weidong Zhang , Yu Zhang , Yixin Wan , Wenting Li, Weifeng Song , Zhongmin Maxwell Wang , Baiyong Li , Michelle Xia , Yunpeng Yang *, Wenfeng Fang （方文峰）*, Yan Huang *, Li Zhang *. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023 Aug 3;62:102106.
29. Lanlan Pang # , Yihua Huang # , Weitao Zhuang # , Yaxiong Zhang # , Jun Liao , Yue Hao , Feng Hao , Guoqian Wang , Ze-Xin Chase Chen , Yu Zhu , Mengzhen Li , Zhengbo Song , Bo Peng Deng , Jing Li , Li Zhang , Wenfeng Fang（方文峰）*. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Clinical Cancer Research. 2024 Jun 14;30(12):2636-2646.
30. Yihua Huang #, Jie Huang, Jianhua Zhan , Maojian Chen , Jiani Zheng , Junyi He , Wenfeng Fang（方文峰）* , Li Zhang* , Jing Li*. CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib. Cell Death Dis. 2025 Apr 15;16(1):303.
六、获奖及荣誉
2022年，“广东省科技进步一等奖”
2021年，“国家高层次人才”
2021年，“中国抗癌协会科技奖一等奖”
2019年，“中国抗癌协会科技奖一等奖”
2019年，“广东医学科技奖一等奖”
2018年，“广东省杰出医学青年人才”
2015年，“广东省特支计划百千万工程青年拔尖人才”
2015年，“广州市珠江科技新星”
2014年，中山大学肿瘤防治中心“临床医学科学家”培养对象
2013年，“中山大学肿瘤防治中心优秀人才”
更新时间：2026.1.30
